© 1997 American Heart Association, Inc.
Articles |
Homocysteine as a Risk Factor for Vascular Disease
Enhanced Collagen Production and Accumulation by Smooth Muscle Cells
From the Department of Cell Biology, Research Institute, Cleveland Clinic Foundation, Ohio. Drs Majors and Pezacka are now affiliated with the Department of Human Genetics, Allegheny University of the Health Sciences, Pittsburgh, Pa.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract An increased plasma homocysteine level is an independent risk factor for vascular disease. However, the pathological mechanisms by which homocysteine promotes atherosclerosis are not yet clearly defined. Arterial smooth muscle cells cultured in the presence of homocysteine grew to a higher density and produced and accumulated collagen at levels significantly above control values. Homocysteine concentrations as low as 50 µmol/L significantly increased both cell density and collagen production. Cell density increased by as much as 43% in homocysteine-treated cultures. Homocysteine increased collagen production in a dose-dependent manner. Smooth muscle cells treated with homocysteine at concentrations observed in patients with hyperhomocysteinemia had collagen synthesis rates as high as 214% of control values. Likewise, collagen accumulation in the cell layer was nearly doubled in homocysteine-treated cultures. Addition of aquacobalamin to homocysteine-treated cultures controlled the increase in smooth muscle cell proliferation and collagen production. These results indicate a cellular mechanism for the atherogenicity of homocysteine and provide insight into a potential preventive treatment.
Key Words: collagen • atherosclerosis • homocysteine • smooth muscle cell • extracellular matrix
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Homocysteine is a sulfhydryl-containing amino acid produced as an intermediate of the methionine conservation cycle and the one-carbon metabolic and transsulfuration pathways (Fig 1
). Normal plasma total Hcy
concentrations range from 5 to 15 µmol/L, and patients
with plasma Hcy concentrations above 15 µmol/L are
considered to have hyperhomocysteinemia.1 Increased levels
of Hcy in human plasma can be caused by either inherited or acquired
conditions. Acquired conditions may be secondary to chronic disorders,
prolonged drug therapy, or an abnormal nutritional state.2
A common polymorphism in the tetrahyrofolate reductase gene
resulting in mild hyperhomocysteinemia is believed to be a risk factor
for cardiovascular disease.3 4
Life-threatening hyperhomocysteinemia, resulting in vascular disease at
a young age, is associated with enzymatic defects at various points of
Hcy metabolism5 6 7 8 (Fig 1). Plasma Hcy levels
can be as high as 500 µmol/L in patients who exhibit
severe atherosclerosis and have either acquired or
inherited functional cobalamin deficiency or cystathionine ß-synthase
deficiency that does not respond to PLP treatment.5 6 7 8 9
|
The methylation of Hcy to regenerate methionine is catalyzed by the
Cbl-dependent enzyme methionine synthase (Fig 1
). Impairment of this
remethylation pathway can result in hyperhomocysteinemia. A correlation
between low serum levels of Cbl and hyperhomocysteinemia has been
observed in a number of severely Cbl-deficient
patients.10 11 Although the serum vitamin B12
(CN-Cbl) assay is an extremely sensitive test for Cbl deficiency, it
lacks specificity. The true intracellular deficiency of biologically
active Cbl, as evidenced by increased plasma Hcy, does not always
correlate with marginally low levels of serum CN-Cbl.12 13
CN-Cbl is not the biologically active form of Cbl; CN-Cbl must be
converted to aqCbl to become a precursor of the Cbl II that is bound by
apo-methionine synthase (Fig 1). Patients with genetically impaired
remethylation of Hcy caused by Cbl C, D, and E mutations involving the
intracellular metabolism of Cbl can have normal plasma Cbl
levels but still be hyperhomocysteinemic.5 6 7 8 Such
patients, when treated with hydroxocobalamin, which is converted to
aqCbl at physiological pH, improve
clinically.14 15 16 Even in normal rats, hydroxocobalamin
infusion enhances liver methionine synthase activity to 132% of
control values and reduces serum Hcy concentrations to 74% of control
levels despite normal plasma levels of CN-Cbl.17
Recently, a strong correlation has been established between elevated levels of plasma Hcy and vascular disease, regardless of the underlying metabolic cause.18 19 Elevated plasma Hcy levels have been found in patients with coronary artery disease, cerebrovascular disease, or peripheral vascular disease.20 21 22 23 24 25 However, the mechanisms by which Hcy promotes atherosclerotic plaque formation are not clearly defined. SMC migration and proliferation and collagen deposition are hallmarks of atherosclerosis. Tsai et al26 27 have demonstrated that short-term exposure of SMCs to Hcy enhances cellular proliferation. These experiments were performed, however, in culture medium that does not contain Cbl. Because only 0.4% serum was used in these experiments, the contribution of Cbl from the serum would be small, only 1 to 2 pmol/L, which may be insufficient for rapidly proliferating cells. It has not been shown whether or not the addition of either CN-Cbl or aqCbl may minimize the mitogenic effect of Hcy on SMCs. The effects of Hcy on SMC collagen synthesis are not known. To further elucidate the pathological mechanisms involved in Hcy-induced atherosclerosis, we examined the effect of Hcy on cell proliferation, collagen synthesis, and collagen accumulation in cultured arterial SMCs.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
All chemicals were purchased from Sigma Chemical Company unless stated otherwise.
Cell Culture
Rabbit aortic SMCs were obtained from explants of the medial
layer from the thoracic aorta of a young male rabbit and cultured as
previously described.28 Briefly, cells were grown in
DME/F12 (1:1) medium (Irvine Scientific) that contained 0.12%
NaHCO3 and 10% FBS (Bio-Whitaker). Amino acid
supplementation (MEM nonessential amino acids supplement, Irvine
Scientific) resulted in a final concentration of 0.25
mmol/L L-proline. The total cyst(e)ine concentration
was within the physiological range (300
µmol/L), and the concentration of CN-Cbl was 500
nmol/L. Cultures were maintained at 37°C in 95% air and 5%
CO2. Unless otherwise stated, six-well tissue-culture
plates (Costar) were used in experiments. SMC cultures from passages 5
to 8 were used. Cultures were confluent within the first week and were
postconfluent for all experiments. SMC cultures were fed 3 to 4 times
per week with medium containing freshly made Hcy.
Hcy Preparation
L-Hcy was prepared from L-Hcy
thiolactone as described29 Briefly, Hcy thiolactone was
dissolved in water, hydrolyzed with KOH for 12 minutes at 45°C,
neutralized with HCl (Fisher Scientific), and cooled to 0°C with
constant nitrogen purging. Freshly prepared Hcy was used in all
experiments.
Collagen and Total Protein Synthesis
Cultures were labeled as previously described28 for
5 hours with 10 µCi/mL L-[2,3-3H]proline
(New England Nuclear) and 2.5x10-4
mol/L sodium ascorbate. The collagen digestion assay
30 31 32 was used to quantify collagen and noncollagenous
protein synthesis. Briefly, culture medium and cell layers were
combined and precipitated on ice with 10% TCA containing 0.5% tannic
acid. Precipitated material was washed extensively at 4°C with 5%
TCA containing 0.25% tannic acid and 1 mmol/L
L-proline. The labeled protein was resuspended in 0.2N NaOH
and an aliquot was subjected to the collagen digestion assay as
described30 31 32 using collagenase form III from
Clostridium histolyticum (Advanced Biofactures). After
overnight digestion at 37°C, TCA and tannic acid were added to final
concentrations of 5% and 0.25%, respectively. The nonprecipitable
material was subjected to scintillation counting to determine the
amount of radioactivity present. The TCA-precipitable material was
resuspended in 0.2N NaOH and an aliquot was denatured with Soluene
(Packard Instrument Co), neutralized with HCl, and subjected to
scintillation counting.
DNA Determination
Cultures were trypsinized, resuspended in phosphate buffer, and
sonicated as described.32 DNA concentration was determined
fluorimetrically by the method of Labarca and Paigen.33
Hydroxyproline Analysis
SMCs were plated sparsely (2.7x102/mm2)
into 100-mm petri dishes (Costar) and grown for 3 weeks in DME/F12
medium containing 10% FBS and 2.5x10-4
mol/L sodium ascorbate with or without 300 µmol/L
Hcy. Conditioned medium was aspirated and cell layers were rinsed twice
with PBS. A solution of 5% TCA/0.25% tannic acid was added and the
petri dishes were placed in a -70°C freezer. Cell layers were later
scraped, centrifuged, and rinsed once in 5% TCA/0.25% tannic
acid. Precipitated protein was resuspended in 6N HCl and hydrolyzed at
120°C for 18 hours. Hydrolysates were filtered, evaporated, and
resuspended in deionized water.28 Hydroxyproline was
assayed colorimetrically by the method of Bergman and
Loxley.34 Hydroxyproline was not detectable in SMCs grown
in the absence of sodium ascorbate.
Data Analysis
Statistical analysis was performed with SPSS for Windows
(SPSS Inc). Statistical comparisons between groups were performed using
ANOVA for multiple comparisons, and when significant, this
analysis was followed by multiple two-tailed Student's
t tests. Differences were considered significant at a value
of P<.05. Pearson's correlation coefficients were
used.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The long-term effects of Hcy on SMCs were determined by growing rabbit aortic SMCs for 3 weeks with or without Hcy in the culture medium. The standard culture medium used in all experiments contained physiological concentrations of Cys and high levels of CN-Cbl. Cell densities increased significantly with increasing concentrations of added Hcy, as indicated by their DNA contents (Fig 2
). DNA content reached a maximum (143%
of control values) at an Hcy concentration of 300 µmol/L,
and this concentration was used in subsequent experiments. All results
have been normalized to the DNA content of the cultures to account for
differing cell numbers.
|
Collagen synthesis by SMCs cultured for 3 weeks in the presence of
increasing concentrations of Hcy increased in a dose-dependent manner
(r2=.99, Fig 3). Adding only 50 µmol/L
Hcy to SMC cultures significantly increased collagen synthesis by 16%.
SMCs treated with 500 µmol/L Hcy synthesized 214% of the
amount of total collagen produced by control cultures.
|
represents collagen synthesis per nanogram DNA and 
,
noncollagenous protein synthesis per nanogram DNA. *P<.01
relative to control SMCs with no added Hcy; **P<.005; and
***P<.001.
Hcy also increased SMC synthesis of noncollagenous proteins, but only
at concentrations of 200 µmol/L and higher (Fig 3).
However, Hcy increased noncollagenous protein synthesis by only 17%
compared with a 114% increase in collagen synthesis.
Collagen synthesis, expressed as a percentage of total protein
synthesis (relative collagen synthesis), also increased incrementally
with increasing concentrations of Hcy
(r2=.96, Fig 4), rising from 2.7% in control cultures
to 4.8% in cultures treated with 500 µmol/L Hcy.
|
Collagen accumulation is the net result of collagen synthesis and
degradation. To determine whether the excess collagen produced by
Hcy-treated cells was accumulating, we assayed the hydroxyproline
contents of the cell layers as a measure of insoluble collagen
accumulation. Fig 5 shows that cell
layers of SMCs grown for only 3 weeks with 300 µmol/L Hcy
accumulated 1.9 times the amount of insoluble collagen per nanogram DNA
than cell layers from control SMCs.
|
To determine whether the free thiol group may be important for
modulating SMC proliferation and collagen synthesis, we also tested the
effects of exogenously added Cys and AdoHcy. The standard culture
medium used in all experiments already contained 300
µmol/L Cys total. Further addition of Cys to a final
concentration of 600 µmol/L, which is twice the
physiological plasma level, increased SMC collagen
synthesis per nanogram DNA to a similar but lesser extent than Hcy (Fig 6). Cys also increased the DNA content of
SMC cultures, but only to 86% of the amount attained by Hcy treatment.
AdoHcy had no effect on either DNA content or collagen synthesis (Fig 6).
|
We analyzed the effect of aqCbl on SMC proliferation and
collagen synthesis by SMCs cultured in the presence of Hcy. Adding
aqCbl to Hcy-treated cultures significantly reduced their DNA contents,
while the DNA contents of cultures treated with aqCbl alone were
similar to control values (Fig 7). The
addition of aqCbl to Hcy-treated cultures also reduced SMC collagen
synthesis per nanogram DNA to nearly half that produced by SMCs
cultured with Hcy alone (Fig 8). Total
protein synthesis induced by Hcy was also significantly reduced by the
addition of aqCbl (Fig 8). However, when SMCs were cultured with aqCbl
alone, neither collagen nor total protein synthesis was affected (Fig 8).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Numerous studies have indicated that even moderate hyperhomocysteinemia is an independent risk factor for vascular disease. Atherosclerosis is characterized by an extensive thickening of the arterial intima that is associated with both SMC proliferation and the excessive deposition of extracellular matrix protein by intimal SMCs.35 36 Collagen is the major component of these atherosclerotic plaques, representing up to 60% of the total protein present.37 We have shown the long-term effects of moderate to high pathophysiological concentrations of Hcy on SMCs by culturing SMCs for 3 weeks with or without Hcy in the culture medium.
Cell density increased with increasing concentrations of Hcy. Hcy concentrations as low as 50 µmol/L, which is only 3.3 times the upper range of Hcy concentrations in normal plasma, significantly increased the DNA content of SMC cultures. These results demonstrate that Hcy, at concentrations found in the plasma of hyperhomocysteinemic patients, can promote the growth of SMCs.
We have also found that the synthesis of collagen by SMCs cultured in the presence of Hcy increased dramatically in a dose-dependent manner. Hcy concentrations as low as 50 µmol/L significantly increased SMC collagen synthesis. SMCs treated with 500 µmol/L Hcy synthesized more than double the amount of collagen produced by control SMCs. Relative collagen synthesis also increased dramatically with increasing Hcy concentrations, indicating a preferential increase in collagen production. In contrast, noncollagenous protein synthesis was increased by only a maximum of 17% and only at Hcy concentrations of 200 µmol/L and higher. These observations show that the enhanced production of collagen was preferential and not simply the result of a general increase in protein synthesis or a higher specific activity of the radiolabeled proline in treated versus control cells.
The increase in SMC collagen synthesis by Hcy was accompanied by an excessive accumulation of insoluble collagen in the cell layer, demonstrating that the excess collagen produced was not simply degraded. This is consistent with the finding that hydroxyproline accumulates in the aortas of rats fed Hcy for 6 weeks.38 Such dramatic increases in collagen synthesis and accumulation over a relatively short period are also consistent with the accumulation of collagen in atherosclerotic plaques in children with premature atherosclerosis resulting from severe hyperhomocysteinemia.5 6 7 8 39
Previous studies have demonstrated that the free thiol group of Hcy is involved in mediating many of the effects of Hcy.27 40 41 42 In agreement with these findings, we showed that Cys but not AdoHcy enhanced SMC proliferation and collagen synthesis, suggesting that the sulfhydryl group of Hcy is likely to be mediating its effects. While providing useful information with respect to the mechanism by which Hcy upregulates SMC proliferation and collagen synthesis, the similar enhancement of these processes by Cys is unlikely to be physiologically relevant, because such high Cys concentrations are not normally observed in vivo. The total plasma cysteine concentration is only 200 to 350 µmol/L.43 44 Patients with defects in the transsulfuration pathway, with cystinuria, or cystinosis do not have elevated plasma levels of cysteine.6 45 46 Only patients requiring hemodialysis have been observed to have dramatically elevated plasma cysteine levels.47 48 However, other amino acids, including Hcy, are also elevated in such patients.47 Because cysteine is believed to be an important regulator of the distribution of Hcy between reduced and oxidized forms,2 it is important for in vitro experiments to use cysteine concentrations in the physiological range. Our findings show that in standard culture medium containing physiological concentrations of cysteine (300 µmol/L), Hcy enhances both SMC proliferation and collagen synthesis.
The addition of aqCbl inhibited the Hcy-induced enhancement of SMC
proliferation, collagen synthesis, and total protein synthesis. When
SMCs were cultured with aqCbl alone, neither cell density, collagen,
nor total protein synthesis was affected. These results suggest that
the observed reduction of the Hcy-induced elevation in collagen and
total protein synthesis by aqCbl is not the result of a toxic effect of
aqCbl. The Cbl-dependent enzyme methionine synthase catalyzes the
methylation of Hcy to regenerate methionine (Fig 1). CN-Hcy is
converted to aqCbl, which is a precursor of the Cbl II that is bound by
apo-methionine synthase (Fig 1). The conversion of CN-Cbl to aqCbl is
catalyzed by the ß-axial ligand transferase/Cbl reductase
complex,49 50 which, in SMCs, is irreversibly inhibited by
Hcy at a concentration of 20 µmol/L or higher and is
noncompetitively inhibited even below this concentration (E.H. Pezacka,
unpublished data, 1996). Adding aqCbl directly to SMC cultures,
however, eliminates the requirement for this enzyme's activity and
allows SMCs to overcome the metabolic block caused by
elevated Hcy concentrations.
In normal human serum, Cbl levels determined as CN-Cbl range from 0.15 to 0.81 nmol/L.51 The standard culture medium (DME/F12) used in these studies contained 500 nmol/L CN-Cbl, a level more than 600 times greater than physiological serum concentrations. Despite these high CN-Cbl concentrations, adding Cbl in the form of aqCbl inhibited Hcy enhancement of collagen synthesis. Recently Selhub et al19 have shown both the lack of correlation between plasma Hcy levels and vitamin B12 intake and that plasma Hcy levels decrease significantly after PLP or folate supplementation. This observation suggested that both PLP and folate, in contrast to CN-Cbl, may induce Hcy catabolism and remethylation, respectively. Our observations suggest that inhibition of the ß-axial ligand transferase/Cbl reductase complex by increased concentrations of Hcy explains, at least in part, the lack of correlation between CN-Cbl supplementation and decreased levels of Hcy in hyperhomocysteinemic patients. These results may also provide insight into potential preventive measures against Hcy-induced atherosclerosis.
Studies reporting the effect of Hcy on cultured cells frequently use both nonphysiological forms and concentrations of Hcy. Concentrations in the millimolar range, up to 10 mmol/L, have often been used, despite plasma concentrations of only 500 µmol/L in the most severe cases of hyperhomocysteinemia.5 6 7 8 9 Commercially available mixtures of the D and L enantiomers of Hcy have also been employed, although only the L form occurs naturally.2 A cyclic form of Hcy, Hcy thiolactone, has been used in other studies. This form has recently been identified as a byproduct of the proofreading function of methionyl-tRNA synthetase.52 However, the pathophysiological consequences of Hcy thiolactone formation still remain controversial; it is not readily detectable in serum because of rapid elimination both by enzymatic hydrolysis to Hcy and by attachment to proteins.53 54 55 In this study, L-Hcy, freshly prepared by the anaerobic alkaline hydrolysis of L-Hcy thiolactone,29 was used at concentrations consistent with plasma Hcy levels found in patients with pathophysiological hyperhomocysteinemia (50 to 500 µmol/L).
Hcy is structurally similar to D-penicillamine (ß,ß-dimethylcysteine) and, like penicillamine, has been reported to have lathyrogenic properties both in vitro and in vivo.56 57 58 In vitro, lathyrogens are frequently employed to inhibit cross-linking of collagen chains, which keeps newly synthesized collagen in a soluble form and prevents its accumulation in the cell layer. Despite this potential effect of Hcy, hydroxyproline analysis showed that SMCs exposed to Hcy accumulated nearly twice the amount of insoluble collagen as control cultures. Furthermore, patients with hyperhomocysteinemia do not display the vascular wall weakness59 that would result from a severe lack of collagen cross-linking. In the plasma of healthy humans, Hcy exists in two major forms: protein-bound and free homodisulfides or mixed disulfides. Plasma proteins have a maximal Hcy-binding capacity of about 150 µmol/L, and the protein-bound fraction accounts for about 70% to 75% of the total Hcy in plasma.60 The remainder may exist as Hcy-cysteine mixed disulfide or as a self-conjugate, homocystine. Less than 0.5% of total plasma Hcy exists in the free reduced form. Increased levels of both reduced free Hcy and homocystine are usually detected in the plasma of patients with hyperhomocysteinemia or homocystinuria, regardless of its cause.2 5 6 7 8 The increased free reduced form of Hcy, however, is insignificant compared with total plasma Hcy, and it is unlikely that the other forms are lathyritic.
Patients with hyperhomocysteinemia have a high incidence of thromboemboli, indicating enhanced thrombogenicity. Previous studies have shown that lathyritic collagen is more effective than normal collagen in aggregating platelets61 and that enhanced platelet deposition is correlated with areas enriched in collagen.62 Desquamation of endothelium by Hcy could temporarily expose the underlying extracellular matrix. The excessive collagen deposition and possibly partial inhibition of collagen cross-linking56 57 in hyperhomocysteinemic patients may alter the matrix, resulting in enhanced thrombogenic properties.
Hcy likely promotes atherogenesis by numerous mechanisms. It has been implicated in endothelial cell dysfunction and has been shown to denude vascular endothelium in vivo63 64 65 and to be cytotoxic to cultured endothelial cells.66 67 68 In contrast, SMC proliferation is stimulated by short-term exposure to Hcy.26 Our results showing enhanced proliferation in long-term cultures of Hcy-treated SMCs corroborate those reported by Tsai et al26 using short-term cultures, even at Hcy concentrations significantly lower than those tested in their studies and in the presence of high CN-Cbl concentrations. Hcy may promote the oxidation of LDL.42 69 Hcy may also play a role in atherosclerotic plaque formation through its potential involvement in generating free radicals.70 The mechanism by which hyperhomocysteinemia influences the excessive connective tissue production seen in occlusive vascular disease has not been established.
The results of our study, combined with previous findings concerning the effect of Hcy on endothelial cells and LDL, delineate possible mechanisms involving Hcy-induced atherosclerosis. It is the first evidence that Hcy at a concentration as low as 50 µmol/L enhances collagen production and accumulation by cultured SMCs. Further Hcy-dependent increases in collagen synthesis are dose dependent. Our data also suggest that Hcy may influence SMC participation in atherosclerosis in two ways. The initial effect would be to promote SMC proliferation and the second would be to promote a specific increase in collagen production and accumulation both in an absolute manner, expressed as collagen synthesis per SMC, and also as an increase relative to total protein synthesis. Administration of aqCbl to inhibit these effects may prove useful in preventing or slowing the progression of atherosclerosis. Current efforts in our laboratory are focused on determining the biochemical mechanisms by which Hcy increases cellular proliferation and upregulates collagen synthesis by SMCs, including Northern blot analysis of procollagen mRNAs, identification of signaling pathways, and identification of which specific forms of Hcy are eliciting its effects. In addition, we are investigating the effects of Hcy on other extracellular matrix components that are believed to be altered in patients with hyperhomocysteinemia.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This study was supported by National Institutes of Health grants DK42122 (to E.H. Pezacka) and HL29582 (to L.A. Ehrhart) and in part by Cleveland Clinic Foundation grant RPC No. 2813 (to E.H. Pezacka).
|
Footnotes |
|---|
Reprint requests to Alana Majors, Department of Human Genetics, Allegheny University of the Health Sciences, Allegheny Campus, Pittsburgh, PA 15212.
Received October 16, 1996; accepted December 11, 1996.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39:1764-1779.[Abstract]
2. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989;114:473-501.[Medline] [Order article via Infotrieve]
3. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.[Medline] [Order article via Infotrieve]
4. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.[Medline] [Order article via Infotrieve]
5. Fenton W, Rosenberg LE. Inherited disorders of cobalamin transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co; 1995:3129-3150.
6. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co; 1995:1279-1328.
7. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co; 1995:3111-3128.
8. Pyeritz RE. Homocystinuria. In: Beighton ed. McKusick's Heritable Disorders of Connective Tissue. St Louis, Mo: Mosby-Year Book Inc; 1993:137-178.
9. Brattstrom L, Israelsson B, Lindgarde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency. Metabolism. 1988;37:175-178.[Medline] [Order article via Infotrieve]
10. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Diagnosis of cobalamin deficiency, I: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol. 1990;34:90-98.[Medline] [Order article via Infotrieve]
11.
Stabler SP, Allen RH, Savage DG, Lindenbaum J.
Clinical spectrum and diagnosis of cobalamin deficiency.
Blood. 1990;76:871-881.
12. Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency, II: relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol. 1990;34:99-107.[Medline] [Order article via Infotrieve]
13. Lindenbaum J, Healton EB, Savage DG, Brust JC, Garrett TJ, Podell ER, Marcell PD, Stabler SP, Allen RH. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318:1720-1728.[Abstract]
14. Rosenblatt DS, Thomas IT, Watkins D, Cooper BA, Erbe RW. Vitamin B12 responsive homocystinuria and megaloblastic anemia: heterogeneity in methylcobalamin deficiency. Am J Med Genet. 1987;26:377-383.[Medline] [Order article via Infotrieve]
15. Schuh S, Rosenblatt DS, Cooper BA, Schroeder ML, Bishop AJ, Seargeant LE, Haworth JC. Homocystinuria and megaloblastic anemia responsive to vitamin B12 therapy: an inborn error of metabolism due to a defect in cobalamin metabolism. N Engl J Med. 1984;310:686-690.[Abstract]
16. Mamlok RJ, Isenberg JN, Rassin DK, Norcross K, Tallan HH. A cobalamin metabolic defect with homocystinuria, methylmalonic aciduria and macrocytic anemia. Neuropediatrics. 1986;17:94-99.[Medline] [Order article via Infotrieve]
17. Stabler SP, Brass EP, Marcell PD, Allen RH. Inhibition of cobalamin-dependent enzymes by cobalamin analogues in rats. J Clin Invest. 1991;87:1422-1430.
18.
Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson
PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg
IH. Association between plasma homocysteine concentrations and
extracranial carotid-artery stenosis. N Engl
J Med. 1995;332:286-291.
19.
Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg
IH. Vitamin status and intake as primary determinants of
homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
20.
Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson
B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of
plasma homocyst(e)ine and risk of myocardial infarction in US
physicians. JAMA. 1992;268:877-881.
21.
Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond
G. Carotid artery intimal-medial wall thickening and plasma
homocyst(e)ine in asymptomatic adults: the
Atherosclerosis Risk in Communities Study.
Circulation. 1993;87:1107-1113.
22. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res. 1993;71:337-359.[Medline] [Order article via Infotrieve]
23. Malinow MR. Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review. Clin Chem. 1995;40:173-176.
24. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.[Abstract]
25.
Boushey CJ, Beresford SAA, Omenn GS, Motulsky
AG. A quantitative assessment of plasma homocysteine as a risk
factor for vascular disease. JAMA. 1995;274:1049-1057.
26.
Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E,
Schlegel R, Lee ME. Promotion of vascular smooth muscle cell
growth by homocysteine: a link to
atherosclerosis. Proc Natl Acad Sci
U S A. 1994;91:6369-6373.
27. Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NES, Tan LC, Haber E, Chang TH, Schlegel R, Lee M. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 1996;97:146-153.[Medline] [Order article via Infotrieve]
28. Majors A, Ehrhart LA. Cell density and proliferation modulate collagen synthesis and procollagen mRNA levels in arterial smooth muscle cells. Exp Cell Res. 1992;200:168-174.[Medline] [Order article via Infotrieve]
29.
Hatch FT, Larrabe AR, Cathou RE, Buchanan JM.
Enzymatic synthesis of the methyl group of methionine.
J Biol Chem. 1961;236:1095-1101.
30. Peterkofsky B, Diegelmann R. Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins. Biochemistry. 1971;10:988-993.[Medline] [Order article via Infotrieve]
31. Peterkofsky B, Chojkier M, Bateman J. Determination of collagen synthesis in tissue and cell culture systems. In: Furthmayr H, ed. Immunohistochemistry of the Extracellular Matrix, II. Boca Raton, Fla: CRC Press; 1982:19-47.
32.
Majors A, Ehrhart LA. Basic fibroblast growth
factor in the extracellular matrix suppresses collagen synthesis and
type III procollagen mRNA levels in arterial smooth muscle
cell cultures. Arterioscler Thromb. 1993;13:680-686.
33. Labarca C, Paigen K. A simple, rapid and sensitive DNA assay procedure. Anal Biochem. 1980;102:344-352.[Medline] [Order article via Infotrieve]
34. Bergman I, Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem. 1963;35:1961-1965.
35. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57:791-804.[Medline] [Order article via Infotrieve]
36. Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J. 1993;69:S30-S37.
37. Barnes MJ. Collagens in atherosclerosis. Coll Rel Res. 1985;5:65-97.[Medline] [Order article via Infotrieve]
38. Lubec B, Arbeiter K, Hoeger H, Lubec G. Increased cyclin dependent kinase in aortic tissue in rats fed homocysteine. Thromb Haemost. 1996;75:542-545.[Medline] [Order article via Infotrieve]
39. McCully KS. Chemical pathology of homocysteine I: atherogenesis. Ann Clin Lab Sci. 1993;23:477-493.[Abstract]
40.
Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers
GM. Homocysteine, a risk factor for premature vascular disease
and thrombosis, induces tissue factor activity in
endothelial cells. Arterioscler
Thromb. 1993;13:1327-1333.
41. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991;88:1906-1914.
42. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta. 1987;917:337-340.[Medline] [Order article via Infotrieve]
43. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Int Med. 1994;236:633-641.[Medline] [Order article via Infotrieve]
44.
Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon
SR, Secic M, Otto JM, Taylor LM. Rapid HPLC determination of
total homocysteine and other thiols in serum and plasma: sex
differences and correlation with cobalamin and folate concentrations in
healthy subjects. Clin Chem. 1994;40:873-881.
45. Segal S, Thier SO. Cystinuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co; 1995:3581-3601.
46. Gahl WA, Schneider JA, Aula PP. Lysosomal transport disorders: cystinosis and sialic acid storage disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co; 1995:3763-3797.
47.
Smolin LA, Laidlaw SA, Kopple JD. Altered plasma
free and protein-bound sulfur amino acid levels in patients undergoing
maintenance hemodialysis. Am J Clin
Nutr. 1987;45:737-743.
48. Bergstrom J, Alvestrand A, Furst P. Plasma and muscle free amino acids in maintenance hemodialysis patients without protein malnutrition. Kidney Int. 1990;38:108-114.[Medline] [Order article via Infotrieve]
49. Pezacka EH. Identification and characterization of two enzymes involved in the intracellular metabolism of cobalamin: cyanocobalamin ß-ligand transferase and microsomal cob(III)alamin reductase. Biochim Biophys Acta. 1993;1157:167-177.[Medline] [Order article via Infotrieve]
50. Pezacka EH, Rosenblatt DS. Intracellular metabolism of cobalamin: altered activities of ß-axial-ligand transferase and microsomal cob(III)alamin reductase in cbl C and cbl D fibroblasts. In: Bhatt R, James VHT, Besser GM, Bottazzo GF, Keen, eds. Advances in Thomas Addison's Diseases. Bristol, UK: Journal of Endocrinology Limited; 1994:315-323.
51. Loeb S. Clinical Laboratory Tests: Values and Implications. Springhouse, Pa: Springhouse Corp; 1993:683-684.
52. Jakubowski H, Goldman E. Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett. 1993;317:237-240.[Medline] [Order article via Infotrieve]
53.
Dudman NPB, Hicks C, Lynch JF, Wilcken DEL, Wang
J. Homocysteine thiolactone disposal by human
arterial endothelial cells and serum in
vitro. Arterioscler Thromb. 1991;11:663-670.
54. McCully KS. Chemical pathology of homocysteine, II: carcinogenesis and homocysteine thiolactone metabolism. Ann Clin Lab Sci. 1994;24:27-59.[Abstract]
55. McCully KS. Chemical pathology of homocysteine, III: cellular function and aging. Ann Clin Lab Sci. 1994;24:134-152.[Abstract]
56. Kang AH, Trelstad RL. A collagen defect in homocystinuria. J Clin Invest. 1973;52:2571-2578.
57. Griffiths R, Tudball N, Thomas J. Effect of induced elevated plasma levels of homocystine and methionine in rats on collagen and elastin structures. Connect Tiss Res. 1976;4:101-106.[Medline] [Order article via Infotrieve]
58. Jackson SH. The reaction of homocysteine with aldehyde: an explanation of the collagen defects in homocystinuria. Clin Chim Acta. 1973;45:215-217.[Medline] [Order article via Infotrieve]
59. Skovby F. The homocystinurias. In: Royce PM, Steinmann B, eds. Connective Tissue and Its Heritable Elements: Molecular, Genetic and Medical Aspects. New York, NY: Wiley-Liss Inc; 1993:469-486.
60. Mansoor MA, Ueland PM, Aarsland A, Svardal AM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria. Metabolism. 1993;42:1481-1485.[Medline] [Order article via Infotrieve]
61. Chesney CM, Harper E, Colman RW. Critical role of the carbohydrate side chains of collagen in platelet aggregation. J Clin Invest. 1972;51:2693-2701.
62. van Zanten GH, de Graaf S, Slootweg PJ, Heijnen HFG, Connolly TM, de Groot PG, Sixma JJ. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest. 1994;93:615-632.
63. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Engl J Med. 1974;291:537-543.
64. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-741.
65.
Harker LA, Harlan JM, Ross R. Effect of
sulfinpyrazone on homocysteine-induced endothelial
injury and arteriosclerosis in baboons.
Circ Res. 1983;53:731-739.
66. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res. 1980;18:113-121.[Medline] [Order article via Infotrieve]
67. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370-1376.
68. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis. 1992;94:89-91.[Medline] [Order article via Infotrieve]
69. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoproteins by thiols: superoxide-dependent and independent mechanisms. J Lipid Res. 1993;34:2051-2061.[Abstract]
70. Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med. 1993;14:683-693.[Medline] [Order article via Infotrieve]
71. Boukhzer E, Ennya A, Felden F, Gerard A, Nexo E, Nicolas JP, Gerard H, Gueant JL. Transcobalamin II-cobalamin binding sites are present on rabbit germ cells. Biochim Biophys Acta. 1992;1175:128-131.[Medline] [Order article via Infotrieve]
72. Banerjee RV, Harder SR, Ragsdale SW, Matthews RG. Mechanism of reductive activation of cobalamin-dependent methionine synthase: an electron paramagnetic resonance spectroelectrochemical study. Biochemistry. 1990;29:1129-1135.[Medline] [Order article via Infotrieve]
73.
Drennan CL, Huang S, Drummond JT, Matthews RG, Ludwig
ML. How a protein binds B12: a 3.0 A X-ray structure
of B12-binding domains of methionine synthase.
Science. 1994;266:1669-1674.
This article has been cited by other articles:
 |
|
 |
|
  E. M. Schwartzfarb and P. Romanelli Hyperhomocysteinemia and Lower Extremity Wounds International Journal of Lower Extremity Wounds, September 1, 2008; 7(3): 126 - 136. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Jiang, J. Jiang, J. Xiong, J. Cao, N. Li, G. Li, and S. Wang Homocysteine-induced extracellular superoxide dismutase and its epigenetic mechanisms in monocytes J. Exp. Biol., March 15, 2008; 211(6): 911 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zittan, M. Preis, I. Asmir, A. Cassel, N. Lindenfeld, S. Alroy, D. A. Halon, B. S. Lewis, A. Shiran, J. E. Schliamser, et al. High frequency of vitamin B12 deficiency in asymptomatic individuals homozygous to MTHFR C677T mutation is associated with endothelial dysfunction and homocysteinemia Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H860 - H865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Mullick, U. B. Zaid, C. N. Athanassious, S. R. Lentz, J. C. Rutledge, and J. D. Symons Hyperhomocysteinemia increases arterial permeability and stiffness in mice Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1349 - R1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Patterson, P R Flatt, L Brennan, P Newsholme, and N H McClenaghan Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic {beta}-cell glucose metabolism and insulin secretion. J. Endocrinol., May 1, 2006; 189(2): 301 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, G. Gregorio, H. Lange, and M. Chiariello Homocysteine and Its Effects on In-Stent Restenosis Circulation, November 8, 2005; 112(19): e307 - e311. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ganji and M. R Kafai Frequent consumption of milk, yogurt, cold breakfast cereals, peppers, and cruciferous vegetables and intakes of dietary folate and riboflavin but not vitamins B-12 and B-6 are inversely associated with serum total homocysteine concentrations in the US population Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1500 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lange, H. Suryapranata, G. De Luca, C. Borner, J. Dille, K. Kallmayer, M. N. Pasalary, E. Scherer, and J.-H. E. Dambrink Folate Therapy and In-Stent Restenosis after Coronary Stenting N. Engl. J. Med., June 24, 2004; 350(26): 2673 - 2681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sundstrom, L. Sullivan, J. Selhub, E. J Benjamin, R. B D'Agostino, P. F Jacques, I. H Rosenberg, D. Levy, P. W.F Wilson, and R. S Vasan Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study Eur. Heart J., March 2, 2004; 25(6): 523 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Soinio, J. Marniemi, M. Laakso, S. Lehto, and T. Ronnemaa Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type 2 Diabetes Mellitus Ann Intern Med, January 20, 2004; 140(2): 94 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rodrigo, W. Passalacqua, J. Araya, M. Orellana, and G. Rivera Homocysteine and Essential Hypertension J. Clin. Pharmacol., December 1, 2003; 43(12): 1299 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Majors, R. C. Austin, C. A. de la Motte, R. E. Pyeritz, V. C. Hascall, S. P. Kessler, G. Sen, and S. A. Strong Endoplasmic Reticulum Stress Induces Hyaluronan Deposition and Leukocyte Adhesion J. Biol. Chem., November 21, 2003; 278(47): 47223 - 47231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Deussen Adenosine--the missing link to understanding homocysteine pathogenicity or more smoke on the horizon? Cardiovasc Res, August 1, 2003; 59(2): 259 - 261. [Full Text] [PDF]
|
|
|
|
|
|
J. Joseph, L. Joseph, N. S. Shekhawat, S. Devi, J. Wang, R. B. Melchert, M. Hauer-Jensen, and R. H. Kennedy Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H679 - H686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Noga, L. M. Stead, Y. Zhao, M. E. Brosnan, J. T. Brosnan, and D. E. Vance Plasma Homocysteine Is Regulated by Phospholipid Methylation J. Biol. Chem., February 14, 2003; 278(8): 5952 - 5955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Joseph, A. Washington, L. Joseph, L. Koehler, L. M. Fink, M. Hauer-Jensen, and R. H. Kennedy Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2567 - H2574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schnyder, Y. Flammer, M. Roffi, R. Pin, and O. M. Hess Plasma homocysteine levels and late outcome after coronary angioplasty J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1769 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hunt and S. C. Tyagi Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation Am J Physiol Cell Physiol, October 1, 2002; 283(4): C1073 - C1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schnyder, M. Roffi, Y. Flammer, R. Pin, and O. M. Hess Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Clinical Outcome After Percutaneous Coronary Intervention: The Swiss Heart Study: A Randomized Controlled Trial JAMA, August 28, 2002; 288(8): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schnyder, M. Roffi, Y. Flammer, R. Pin, and O.M. Hess Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty Eur. Heart J., May 1, 2002; 23(9): 726 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, X. Jiang, F. Yang, G. B. Chapman, W. Durante, N. E. S. Sibinga, and A. I. Schafer Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition Blood, February 1, 2002; 99(3): 939 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schnyder, M. Roffi, R. Pin, Y. Flammer, H. Lange, F. R. Eberli, B. Meier, Z. G. Turi, and O. M. Hess Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels N. Engl. J. Med., November 29, 2001; 345(22): 1593 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Garcia-Tevijano, C. Berasain, J. A. Rodriguez, F. J. Corrales, R. Arias, A. Martin-Duce, J. Caballeria, J. M. Mato, and M. A. Avila Hyperhomocysteinemia in Liver Cirrhosis: Mechanisms and Role in Vascular and Hepatic Fibrosis Hypertension, November 1, 2001; 38(5): 1217 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhou, J. Moller, C. C. Danielsen, J. Bentzon, H. B. Ravn, R. C. Austin, and E. Falk Dietary Supplementation With Methionine and Homocysteine Promotes Early Atherosclerosis but Not Plaque Rupture in ApoE-Deficient Mice Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1470 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. TSUKAMOTO and S. C. LU Current concepts in the pathogenesis of alcoholic liver injury FASEB J, June 1, 2001; 15(8): 1335 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. J. Vermeulen, H. W. M. Niessen, M. Bogels, C. D. A. Stehouwer, J. A. Rauwerda, and V. W. M. van Hinsbergh Decreased Smooth Muscle Cell/Extracellular Matrix Ratio of Media of Femoral Artery in Patients With Atherosclerosis and Hyperhomocysteinemia Arterioscler. Thromb. Vasc. Biol., April 1, 2001; 21(4): 573 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J Riddell, A. Chisholm, S. Williams, and J. I Mann Dietary strategies for lowering homocysteine concentrations Am. J. Clinical Nutrition, June 1, 2000; 71(6): 1448 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Manzi Systemic lupus erythematosus: a model for atherogenesis? Rheumatology, April 1, 2000; 39(4): 353 - 359. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fonseca, S. C. Guba, and L. M. Fink Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis Endocr. Rev., October 1, 1999; 20(5): 738 - 759. [Abstract] [Full Text]
|
|
|
|
|
|
J. Y. Jeremy, D. Rowe, A. M. Emsley, and A. C. Newby Nitric oxide and the proliferation of vascular smooth muscle cells Cardiovasc Res, August 15, 1999; 43(3): 580 - 594. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Rekhter Collagen synthesis in atherosclerosis: too much and not enough Cardiovasc Res, February 1, 1999; 41(2): 376 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ross Atherosclerosis -- An Inflammatory Disease N. Engl. J. Med., January 14, 1999; 340(2): 115 - 126. [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Jacobsen Homocysteine and vitamins in cardiovascular disease Clin. Chem., August 1, 1998; 44(8): 1833 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Kuller and R. W. Evans Homocysteine, Vitamins, and Cardiovascular Disease Circulation, July 21, 1998; 98(3): 196 - 199. [Full Text] [PDF]
|
|
|
|
|
|
V. S. Mujumdar, C. M. Tummalapalli, G. M. Aru, and S. C. Tyagi Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR Am J Physiol Cell Physiol, May 1, 2002; 282(5): C1009 - C1015. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||